Novavax
Gaithersburg
Maryland
United States
649 articles with Novavax
-
Clinical Catch-Up: June 14-18
6/21/2021
It was another busy week of clinical trial announcements. Here’s a look. -
Novavax to Participate in National Vaccine Advisory Committee Meeting
6/17/2021
Novavax, Inc. today announced that Gregory M. Glenn , M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services' National Vaccine Advisory Committee (NVAC).
-
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
6/17/2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2nd Annual CybeRx Series: Vaccine Forum
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
6/14/2021
Novavax, Inc., announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial.
-
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
6/14/2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine
-
The study also found the vaccine was 100% effective at preventing moderate and severe disease.
-
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
6/11/2021
Novavax, Inc today announced preclinical and clinical data on the company's recombinant protein COVID-19 vaccine candidate, NVX-CoV2373
-
Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
6/9/2021
Novavax, Inc. will host Maryland Governor Larry Hogan at the site of the company's planned Vaccines Innovation Campus and global headquarters in Gaithersburg on Thursday, June 10 at 9:30 AM ET .
-
Novavax to Participate in Panel at BIO Digital 2021
6/7/2021
Novavax, Inc. (Nasdaq: NVAX), today announced that Stanley C. Erck, President and Chief Executive Officer, will participate in a panel discussion at the BIO International Convention 2021 on June 14
-
Novavax to Participate in Jefferies Virtual Healthcare Conference
5/27/2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat and host meetings with investors at the upcoming Jefferies Virtual Healthcare Conference.
-
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
5/24/2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn , M.D., President of Research and Development, will present on NVX-CoV2373
-
Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
5/22/2021
Novavax, Inc. announced the signing of a non-binding memorandum of understanding with the Ministry of Health and Welfare of Korea and SK bioscience, Co. Limited, a vaccine business subsidiary of SK Group, to explore further cooperation in the development and manufacturing of vaccines, including NVX-CoV2373, Novavax' recombinant protein COVID-19 vaccine candidate.
-
Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
5/21/2021
- Novavax named Life Sciences Company of the Year - Stanley C. Erck named Life Sciences Chief Executive Officer of the Year
-
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19
5/19/2021
Halberd Corporation was featured in a recent MarketWatch article, "New Approaches to Covid-19 Treatment Enter the Picture," along with six other notable biotechnology companies.
-
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
5/10/2021
- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of publication
-
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
5/10/2021
Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2021.
-
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
5/6/2021
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that it has finalized an advance purchase agreement with Gavi, the Vaccine Alliance for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility.
-
While the U.S. had been one of a few rich nations holding out – along with Canada, the European Union and Britain – on some level, Wednesday’s announcement of support for the proposal is not unexpected.